GRM1 and melanoma: The observation that melanoma cell lines released high levels of glutamate, resulting in a glutamate-based autocrine activation of GRM1 [24], prompted our group to consider riluzole as a potential therapeutic agent acting through the inhibition of glutamate release from melanoma cells [23], [24], [25], [27], [42].